Trial Profile
A Retrospective and Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed TED-C13-003
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jun 2021
Price :
$35
*
At a glance
- Drugs Teduglutide (Primary)
- Indications Short bowel syndrome
- Focus Adverse reactions
- Sponsors Shire; Takeda
- 30 Nov 2020 Status changed from active, no longer recruiting to completed.
- 28 Nov 2020 This trial has been completed in the United Kingdom according to European Clinical Trials Database record.
- 28 Sep 2020 Planned End Date changed from 30 Jun 2020 to 14 Jan 2021.